Why is Aspira Pathlab falling/rising?

As of 10-Jul, Aspira Pathlab & Diagnostics Ltd's stock price is currently at 53.50, reflecting an increase of 1.04 or 1.98%. The stock has shown a trend reversal, gaining after seven consecutive days of decline. Despite this recent uptick, the stock has underperformed in the short term, with a 1-week return of -3.98% compared to a negligible change in the Sensex of -0.06%. However, the stock has outperformed its sector by 2.98% today, and there has been a rise in investor participation, with delivery volume increasing by 5.36% against the 5-day average. The company has reported positive financial results over the last four quarters, with significant growth in both profit after tax and net sales, contributing to a strong return of 72.58% over the past year.
In the broader market context, while Aspira Pathlab's recent performance has been volatile, it has still managed to outperform the BSE500 index, which has only returned 1.46% over the same period. The stock's long-term fundamentals, however, raise concerns, as it has a weak ability to service its debt, indicated by a poor EBIT to Interest ratio. Despite trading at a discount compared to its peers and having a favorable PEG ratio, the stock's long-term growth in operating profits has been modest at a CAGR of 19.70% over the last five years, which may contribute to investor caution.